Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sam, Lawn"'
Autor:
Mario Sanches, Igor D’Angelo, Maria Jaramillo, Jason Baardsnes, John Zwaagstra, Joe Schrag, Ian Schoenhofen, Mauro Acchione, Sam Lawn, Grant Wickman, Nina Weisser, David K. Y. Poon, Gordon Ng, Surjit Dixit
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
As biologics have become a mainstay in the development of novel therapies, protein engineering tools to expand on their structural advantages, namely specificity, affinity, and valency are of interest. Antibodies have dominated this field as the pref
Externí odkaz:
https://doaj.org/article/a5ed50a220974d43b325471bef850d35
Autor:
Graham Garnett, Katina Mak, Renee Duan, Truman Hirkala-Schaefer, Manuel Lasalle, Nichole Escalante, Joy Guedia, Kara Moyes, Sam Lawn, Raffaele Colombo, Jamie Rich, Stuart Barnscher
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Mark R. Flory, Gang Chen, Matthew E.K. Chang, Martin E. Gleave, Chia-Chi Flora Huang, Robert N. Young, Nathan A. Lack, Fariba Ghaidi, Hélène Morin, Fuqiang Ban, Shreyas Lingadahalli, Ayse Derya Cavga, Ivan Pak Lok Yu, Sam Lawn, Sankar Mohan, Eric Leblanc, Paul S. Rennie, Nada Lallous, Artem Cherkasov, Hisham Mohammed
Publikováno v:
Journal of Medicinal Chemistry. 64:14968-14982
Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC.
Autor:
Sam Lawn, Andrea Hernandez Rojas, Raffaele Colombo, Dayananda Siddappa, Jodi Wong, Kaylee Wu, Vincent Fung, Dunja Urosev, Luying Yang, Jamie R. Rich, Stuart D. Barnscher
Publikováno v:
Cancer Research. 83:2641-2641
Background: Folate Receptor alpha (FRa) is a validated cell surface cancer target that is prevalently expressed in multiple cancers with high unmet need, including ovarian cancer and other gynecological cancers, while exhibiting minimal expression in
Autor:
Eric, Leblanc, Fuqiang, Ban, Ayse Derya, Cavga, Sam, Lawn, Chia-Chi Flora, Huang, Sankar, Mohan, Matthew E K, Chang, Mark R, Flory, Fariba, Ghaidi, Shreyas, Lingadahalli, Gang, Chen, Ivan Pak Lok, Yu, Hélène, Morin, Nada, Lallous, Martin E, Gleave, Hisham, Mohammed, Robert N, Young, Paul S, Rennie, Nathan A, Lack, Artem, Cherkasov
Publikováno v:
Journal of medicinal chemistry. 64(20)
Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC.
Autor:
Grant Wickman, Sam Lawn, Joe Schrag, Gordon Yiu Kon Ng, Nina E. Weisser, David Kai Yuen Poon, Mario Sanches, Maria L. Jaramillo, Jason Baardsnes, Mauro Acchione, Igor Edmondo Paolo D'angelo, John C. Zwaagstra, Ian Schoenhofen, Surjit Bhimarao Dixit
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
As biologics have become a mainstay in the development of novel therapies, protein engineering tools to expand on their structural advantages, namely specificity, affinity, and valency are of interest. Antibodies have dominated this field as the pref
Autor:
Carmen Binding, Cameron J. Grisdale, Matthaeus Ware, Nick Chahley, Kaitlin Thomas, Haley Pedersen, Michael D. Blough, Hiba Omairi, Jessica DePetro, J. Gregory Cairncross, Alexandra Bohm, Sam Lawn, Shazreh Bukhari, Amanda Gerber, Cindy Chen
Publikováno v:
Neuro Oncol
IDH-wildtype GBM is the most common variant of this cancer and occurs in older adults. Unfortunately patients’ tumors are either inherently resistant to standard treatment, which includes radio- and chemo-therapy, or acquire resistance during the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2574160c3eb9b44b7e7527ee69a2259
https://europepmc.org/articles/PMC6846813/
https://europepmc.org/articles/PMC6846813/
Autor:
Peter Axerio-Cilies, Paul S. Rennie, Takeshi Yamazaki, Ari Kim, Miriam S. Butler, Sam Lawn, Michael E. Cox, Yubin Guo, Fariba Ghaidi, Scott Lien, Mannan Nouri, Marta Mroczek, Lawrence P. McIntosh, Cheryl Y. Gregory-Evans, Artem Cherkasov, Martin E. Gleave, Kush Dalal, Mani Roshan-Moniri, Desmond K. W. Lau, Paul M. Yen, Michael Hsing, Clement Yau
Publikováno v:
Oncotarget
// Miriam S. Butler 1, *, # , Mani Roshan-Moniri 1, *, # , Michael Hsing 1, *, # , Desmond Lau 2, *, # , Ari Kim 1 , Paul Yen 1 , Marta Mroczek 1 , Mannan Nouri 1 , Scott Lien 1 , Peter Axerio-Cilies 1 , Kush Dalal 1 , Clement Yau 1 , Fariba Ghaidi 1
Autor:
Paul S. Rennie, Sam Lawn, Eric Leblanc, Fariba Ghaidi, Ian G. Mills, Fuqiang Ban, Artem Cherkasov, Martin E. Gleave, Nada Lallous, Lavinia A. Carabet, Hélène Morin, Joseph Lee
Publikováno v:
Carabet, L A, Lallous, N, Leblanc, E, Ban, F, Morin, H, Lawn, S, Ghaidi, F, Lee, J, Mills, I G, Gleave, M E, Rennie, P S & Cherkasov, A 2018, ' Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer ', European journal of medicinal chemistry, vol. 160, pp. 108-119 . https://doi.org/10.1016/j.ejmech.2018.09.023
While Myc is an essential regulator of growth in normal cells, it is also frequently associated with cancer progression, therapy-resistance and lethal outcomes in most human cancers. In prostate cancer (PCa), Myc transcription factors are implicated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fdac4bbea9bcb66582e024e18880f02
https://doi.org/10.1016/j.ejmech.2018.09.023
https://doi.org/10.1016/j.ejmech.2018.09.023
Autor:
Kriti Singh, Mani Roshan-Moniri, Takeshi Yamazaki, Emma S. Tomlinson Guns, Nada Lallous, Shannon Awrey, Artem Cherkasov, Paul S. Rennie, Mads Daugaard, Robert N. Young, Hans Adomat, Mohamed D.H. Hassona, Ravi Shashi Nayana Munuganti, Sam Lawn, Nader Al Nakouzi, Eric Leblanc, Christophe André, Hélène Morin
Publikováno v:
Molecular cancer therapeutics. 15(12)
The development of new antiandrogens, such as enzalutamide, or androgen synthesis inhibitors like abiraterone has improved patient outcomes in the treatment of advanced prostate cancer. However, due to the development of drug resistance and tumor cel